Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1

Conditions

Uterine Cervical Neoplasms 2Recurrence 2Neoplasms 2Neoplasm Metastasis 2Vulvar Neoplasms 1Vaginal Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Penile Neoplasms 1Oropharyngeal Neoplasms 1Head and Neck Squamous Cell Cancer 1Head and Neck Neoplasms 1Anus Neoplasms 1Anal Canal Carcinoma 1

Interventions

Cisplatin 75Cetuximab 63Radiotherapy 38pembrolizumab 29Radiotherapy, Intensity-Modulated 28Carboplatin 25Fluorouracil 24Docetaxel 24Paclitaxel 19Erlotinib Hydrochloride 13Nivolumab 12Radiation 10Pemetrexed 10durvalumab 8Gemcitabine 8Drug Therapy 8Bevacizumab 7zalutumumab 6Surgical Procedures, Operative 6Panitumumab 6Lapatinib 6Everolimus 6Albumin-Bound Paclitaxel 6130-nm albumin-bound paclitaxel 6epacadostat 5Standard of Care 5Oxaliplatin 5Gefitinib 5Afatinib 5Radiosurgery 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Head and Neck Neoplasms × MEDI0457 × Clear all
NCT03162224 2022-08-25

Safety and Efficacy of MEDI0457 and Durvalumab in Participants With Human Papilloma Virus (HPV) Associated Recurrent/Metastatic Head and Neck Cancer

MedImmune LLC

Phase 1/2 Completed
35 enrolled 25 charts
Head & Neck

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms, Neoplasm Metastasis, Neoplasms, Oropharyngeal Neoplasms, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡